Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence
Short Description
This will be a preliminary assessment of the efficacy and safety of three wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce cocaine use in subjects with cocaine dependence and to determine the optimal dose of ondansetron.
Release Date
Aug 01, 2016

The primary objective of this study is to conduct a preliminary assessment of the possible efficacy of ondansetron to reduce cocaine use in outpatients with cocaine dependence.  Hypotheses are that ondansetron will increase the weekly mean proportion of cocaine non-use days assessed by self report of use and confirmed by urine assays for BE, that the weekly proportion of BE positive urines will be decreased, and that the total number of cocaine-free urines will be increased in groups treated with ondansetron when compared to placebo controls.  The results of this study will be used to design subsequent larger studies to confirm the efficacy of ondansetron. This study is also intended to gather preliminary information on biological or psychosocial characteristics of patients who may show better ondansetron treatment responsiveness. In particular, biological measures reflecting individual differences in serotonergic function are included.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents
Case Report Form(s)
Deidentification Notes
Nulled Values
All Documents